Related Experiment Video

Updated: Jun 6, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Novel strategies for treating relapsed/refractory urothelial carcinoma

Gopa Iyer1, Matthew I Milowsky, Dean F Bajorin

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

Expert Review of Anticancer Therapy
|November 30, 2010
PubMed

Insights

Advanced urothelial cancer has a poor prognosis, with limited progress in treatment for 30 years. Novel agents and targeted therapies are crucial for improving outcomes in this challenging disease.

Area of Science:

  • Oncology
  • Urothelial Carcinogenesis
  • Drug Development

Background:

  • Advanced urothelial cancer presents a significant clinical challenge with a poor prognosis.
  • Platinum-based chemotherapy, developed three decades ago, remains a primary treatment but lacks substantial recent advancements.
  • There is a critical need for novel therapeutic strategies to overcome treatment resistance and improve patient survival.

Purpose of the Study:

  • To review the current treatment landscape for advanced urothelial cancer.
  • To discuss emerging novel agents and therapeutic combinations currently in development.
  • To highlight the role of molecular alterations in defining new therapeutic targets.

Main Methods:

  • Literature review of current and emerging treatments for advanced urothelial cancer.
  • Analysis of clinical trial data for novel chemotherapeutic drugs and targeted inhibitors.
  • Discussion of the molecular basis of urothelial tumorigenesis and its implications for therapy.

Main Results:

  • The current standard of care for advanced urothelial cancer has seen limited progress over the past 30 years.
  • Numerous novel agents, including targeted therapies and new chemotherapeutic combinations, are under investigation.
  • Understanding molecular alterations is paving the way for personalized therapeutic approaches.

Conclusions:

  • There is an urgent need for innovative treatments beyond traditional chemotherapy for advanced urothelial cancer.
  • Novel therapeutic agents targeting specific molecular pathways show promise for improving patient outcomes.
  • Continued research and clinical trials are essential to define the next generation of urothelial cancer therapies.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.